


SUPPLEMENTARY MATERIALS



Supplementary Figure 1: Dose validation of secondary pharmaceutical agents in combination with Resminostat against HCC. Sc-1 (1 μ M, 5 μ M, 10 μ M), Cisplatin (5 μ M, 10 μ M), Doxorubicin (0.5 μ M, 1 μ M), DZNep (5 μ M, 10 μ M, 20 μ M) and GSK343 (2 nM, 4 nM, 7 nM) were used in dose validation in HCC cells examining their optimised dose for anti-proliferative effect (n = 3). Proliferation was measured with FluoroFire-Blue ProViaTox assay and presented as fold change compared to control (untreated cells).

Supplementary Table 1: Primer sequences

Gene Name	Sequence
β-Actin (ACTβ)	Forward: 5'-CCTTGCACATGCCGGAG-3'
	Reverse: 5'-GCACAGAGCCTCGCCTT-3'
HDAC 1	Forward: 5'-CATCTCCTCAGCATTGGCTT-3'
	Reverse: 5'-GACGGGGATGTTGGAAATTA-3'
HDAC 2	Forward: 5'-CAGCAAGTTATGGGTCATGC-3'
	Reverse: 5'-CCATGGCGTACAGTCAAGGA-3'
HDAC 3	Forward: 5'-GTTGTTTCAGCTGGGTTGCTC-3'
	Reverse: 5'-GAGAGTCAGCCCCACCAATA-3'
HDAC 6	Forward: 5'-TCCAAGGCACATTGATGGTA-3'
	Reverse: 5'-CACAGTTCACCTTCGACCAG-3'
HDAC 8	Forward: 5'-CCAGCACATAATCAGGACCA-3'
	Reverse: 5'-ATTTTGGGAGGAGGAGGCTA-3'
Caspase 3	Forward: 5'-GAGTCCATTGATTTCGCTTCC-3'
	Reverse: 5'-TCTGGTTTTTCGGTGGGTG-3'
Caspase 7	Forward: 5'-TGCCCAGCTTTTCAAAATTC-3'
	Reverse: 5'-TCAGTGGATGCTAAGCCAGA-3'
Caspase 8	Forward: 5'-CGGAATGTAGTCCAGGCTCA-3'
	Reverse: 5'-GGTCACTGAACCTTGGGAA-3'
Caspase 9	Forward: 5'-CACGGCAGAAGTTCACATTG-3'
	Reverse: 5'-ACACCCAGACCAGTGGACAT-3'
BCL-2	Forward: 5'-CGTACAGTTCACAAAAGGCA-3'
	Reverse: 5'-ATGTGTGTGGAGAGCGTCAA-3'
BAX (BCL2L4)	Forward: 5'-GGAGGAAGTCCAATGTCCAG-3'
	Reverse: 5'-TCTGACGGCAACTTCAACTG-3'
BIM (BCL2L11)	Forward: 5'-CCCTCCTGCATAGTAAGCG-3'
	Reverse: 5'-CCAGGCCTTCAACCACTATC-3'
BAD (BCL2L8)	Forward: 5'-GGTAGGAGCTGTGGCGACT-3'
	Reverse: 5'-GCTCCGGCAAGCATCAT-3'
Cyclin D1 (CCND1)	Forward: 5'-TGAGGCGGTAGTAGGACAGG-3'
	Reverse: 5'-GACCTTCGTTGCCCTCTGT-3'
P21 (CDKN1A)	Forward: 5'-GCCATTAGCGCATCACAGT-3'
	Reverse: 5'-ACCGAGGCACTCAGAGGAG-3'
P27 (CDKN1B)	Forward: 5'-ACAGGATGTCCATTCCATGA-3'
	Reverse: 5'-GGCCTCAGAAGACGTCAAAC-3'
TNFα	Forward: 5'-AGATGATCTGACTGCCTGGG-3'
	Reverse: 5'-CAGCCTCTTCTCCTTCTGA-3'
VEGF	Forward: 5'-CACACAGGATGGCTTGAAGA-3'
	Reverse: 5'-AGGGCAGAATCATCACGAAG-3'
Leptin	Forward: 5'-GACTTTTTGGATGGGCACAG-3'
	Reverse: 5'-GTAGGAATCGCAGCGCC-3'
IL-10	Forward: 5'-GCCACCCTGATGTCTCAGTT-3'
	Reverse: 5'-GTGGAGCAGGTGAAGAATGC-3'
STAT3	Forward: 5'-GGCCATCCTGCTAAAATCAG-3'
	Reverse: 5'-GTCTCTCCCCCTCGGCT-3'
P16 (CDKN2A)	Forward: 5'-GGTCGGGTGAGAGTGGC-3'
	Reverse: 5'-CCCAACGCACCGAATAGTTA-3'
EZH2	Forward: 5'-GCCAACAACTGGTCCCTT-3'
	Reverse: 5'-GGACTCAGAAGGCAGTGGAG-3'
ZFP64	Forward: 5'-GTGACTTGGCAGGGAGAGAG-3'
	Reverse: 5'-ACCACCAGAACCATCACCTC-3'
HSP90	Forward: 5'-CAATGACATCAACTGGGCAA-3'
	Reverse: 5'-CTGTGCCGTTGGTCCCTGT-3'
P65 (RELA)	Forward: 5'-TTTCTCCTCAATCCGGTGAC-3'
	Reverse: 5'-ACCCCTCCCTACGCAGAC-3'